Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Qiagen ( (QGEN) ).
QIAGEN has disclosed a managers’ transaction under market abuse regulations involving supervisory board member Ross Levine. Following his step-down from the Supervisory Board, an automated vesting was triggered that released 22,959 restricted stock units into common shares, with a subsequent net settlement resulting in the receipt of 9,870 shares after the company withheld a portion to cover taxes and related costs. The transaction, executed outside a trading venue on January 23, 2026, reflects routine equity-based compensation mechanics rather than an open-market share purchase or sale, and signals the ongoing use of share-based incentives for governance-level executives at the company.
The most recent analyst rating on (QGEN) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences company whose shares are listed on multiple European exchanges as well as the NYSE and Swiss venues. The company focuses on molecular diagnostics and sample preparation technologies for laboratories, healthcare providers and research institutions, serving global markets through its diversified listing and international investor base.
Average Trading Volume: 1,765,258
Technical Sentiment Signal: Buy
Current Market Cap: $11.21B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.